Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CT-1530 in Relapsed/Refractory B-Cell Malignancies
NCT02981745Phase 2Unknown
- Sponsor
- Centaurus Biopharma Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CT-1530 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM) and 3 more, sponsored by Centaurus Biopharma Co., Ltd. Primary endpoint: Incidence rate of dose limiting toxicities at 28 days. Status: unknown.
02
Drugs
CT-1530
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02981745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981745.